The cell or the egg? A new influenza vaccine for 2024

1. Tenforde MW, Patel MM, Lewis NM, et al. Vaccine effectiveness against influenza A(H3N2)-associated hospitalized illness: United States, 2022. Clin Infect Dis 2023;76(6):1030–37.

2. Sullivan SG, Chilver MB, Carville KS, et al. Low interim influenza vaccine effectiveness, Australia, 1 May to 24 September 2017. Euro Surveill 2017;22(43):17-00707.

3. Boikos C, Fischer L, O’Brien D, et al. Relative effectiveness of the cell-derived inactivated quadrivalent influenza vaccine versus egg-derived inactivated quadrivalent influenza vaccines in preventing influenza-related medical encounters during the 2018-2019 influenza season in the United States. Clin Infect Dis 2021;73(3):e692–98.

4.ESR. Recommendation for Seasonal Influenza Vaccine Composition for New Zealand for 2024. October 2023. https://www.esr.cri.nz/digital-library/influenza-vaccine-recommendations-report-for-2024/

5. Sah P, Medlock J, Fitzpatrick MC, et al. Optimizing the impact of low-efficacy influenza vaccines. Proc Natl Acad Sci U S A 2018;115(20):5151–56.

6. Coleman BL, Gutmanis I, McGovern I, Haag M. Effectiveness of cell-based quadrivalent seasonal influenza vaccine: A systematic review and meta-analysis. Vaccines (Basel) 2023;11(10):1607.

7. Boikos C, Sylvester GC, Sampalis JS, Mansi JA. Relative effectiveness of the cell-cultured quadrivalent influenza vaccine compared to standard, egg-derived quadrivalent influenza vaccines in preventing influenza-like illness in 2017-2018. Clin Infect Dis 2020;71(10):e665–71.

8. Divino V, Krishnarajah G, Pelton SI, et al. A real-world study evaluating the relative vaccine effectiveness of a cell-based quadrivalent influenza vaccine compared to egg-based quadrivalent influenza vaccine in the US during the 2017-2018 influenza season. Vaccine 2020;38;6334–43.

9. Krishnarajah G, Divino V, Postma MJ, et al. Clinical and economic outcomes associated with cell-based quadrivalent influenza vaccine vs. standard-dose egg-based quadrivalent influenza vaccines during the 2018–2019 influenza season in the United States. Vaccines (Basel) 2021;9(2):80.

10. Boikos C, McGovern I, Molrine D, et al. Review of analyses estimating relative vaccine effectiveness of cell-based quadrivalent influenza vaccine in three consecutive US influenza seasons. Vaccines (Basel) 2022;10(6):896.